{
    "title": "GSK's blood cancer drug fails main goal of trial, shares fall",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11398143/GSKs-blood-cancer-drug-fails-main-goal-trial-shares-fall.html",
    "date": "2022-11-07",
    "keywords": [
        "drug",
        "blenrep",
        "approval",
        "treatment",
        "question",
        "gsk",
        "myeloma",
        "trial",
        "data",
        "health",
        "pushkala",
        "aripaka",
        "cancer",
        "market",
        "company",
        "oncology",
        "pomalidomide",
        "analyst",
        "comment",
        "goal",
        "latestage",
        "study",
        "area",
        "focus",
        "standalone",
        "prescription",
        "medicine",
        "vaccine",
        "business",
        "statement",
        "endpoint",
        "survival",
        "period",
        "time",
        "person",
        "disease",
        "april",
        "developer",
        "sierra",
        "access",
        "blood",
        "combination",
        "steroid",
        "dexamethasone",
        "celgene",
        "part",
        "superiority",
        "dreamm3",
        "jpmorgan",
        "note",
        "approvability",
        "setting",
        "success",
        "price",
        "risk",
        "category",
        "amna",
        "karimi",
        "bengaluru",
        "editing",
        "rashmi",
        "uttareshv",
        "fenton"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}